Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma
DJ Kim, J Kim, K Spaunhurst, J Montoya… - Journal of clinical …, 2014 - ascopubs.org
Purpose Itraconazole, a US Food and Drug Administration–approved antifungal drug,
inhibits the Hedgehog (HH) signaling pathway, a crucial driver of basal cell carcinoma (BCC) …
inhibits the Hedgehog (HH) signaling pathway, a crucial driver of basal cell carcinoma (BCC) …
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
MR Migden, NI Khushalani, ALS Chang… - The lancet …, 2020 - thelancet.com
… squamous cell carcinoma. Patients with locally advanced cutaneous squamous cell carcinoma
… of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma. …
… of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma. …
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
T Kudo, Y Hamamoto, K Kato, T Ura, T Kojima… - The Lancet …, 2017 - thelancet.com
… We did an open-label, single-arm, multicentre phase 2 study. Eligible patients had advanced
squamous-cell carcinoma, adenosquamous-cell carcinoma, or adenocarcinoma of the …
squamous-cell carcinoma, adenosquamous-cell carcinoma, or adenocarcinoma of the …
[HTML][HTML] Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N Basset-Séguin, A Hauschild, R Kunstfeld… - European journal of …, 2017 - Elsevier
… Further evaluation of STEVIE showed that 51 patients (4%) with advanced BCC experienced
cutaneous squamous cell carcinoma (SCC). Most patients were aged >75 years with …
cutaneous squamous cell carcinoma (SCC). Most patients were aged >75 years with …
… phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and …
JB Vermorken, J Trigo, R Hitt, P Koralewski… - Journal of clinical …, 2007 - ascopubs.org
Purpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
N Basset-Seguin, A Hauschild, JJ Grob… - The Lancet …, 2015 - thelancet.com
… open-label trial, adult patients with histologically confirmed locally advanced basal cell
carcinoma or metastatic basal cell carcinoma … Patients with locally advanced basal cell carcinoma …
carcinoma or metastatic basal cell carcinoma … Patients with locally advanced basal cell carcinoma …
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
… Because our study was open label, we did not mask patients or investigators to treatment
assignment. However, the funder was unaware of the aggregated by-treatment data summary …
assignment. However, the funder was unaware of the aggregated by-treatment data summary …
… of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
TY Seiwert, B Burtness, R Mehra, J Weiss… - The lancet …, 2016 - thelancet.com
… an open-label, multicentre, phase 1b trial of patients with recurrent or metastatic squamous
cell carcinoma … of recurrent or metastatic squamous cell carcinoma of the head and neck, and …
cell carcinoma … of recurrent or metastatic squamous cell carcinoma of the head and neck, and …
… single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma
C Wülfing, JPH Machiels, DJ Richel, MO Grimm… - Cancer, 2009 - Wiley Online Library
BACKGROUND: The treatment of recurrent transitional cell carcinoma (TCC) remains an unmet
clinical need. This study assessed lapatinib, a dual tyrosine kinase inhibitor of epidermal …
clinical need. This study assessed lapatinib, a dual tyrosine kinase inhibitor of epidermal …
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
HL Kaufman, J Russell, O Hamid, S Bhatia… - The lancet …, 2016 - thelancet.com
Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
相关搜索
- randomised open label cell carcinoma
- merkel cell carcinoma
- head and neck cell carcinoma
- basal cell carcinoma
- metastatic renal cell carcinoma
- recurrent or metastatic head cell carcinoma
- vismodegib in patients cell carcinoma
- efficacy and safety cell carcinoma
- patients with advanced renal cell carcinoma
- randomised open label phase 3 trial
- hedgehog pathway inhibition cell carcinoma
- cemiplimab in patients cell carcinoma
- phase 2 study cell carcinoma
- pembrolizumab or everolimus cell carcinoma
- expansion cohort cell carcinoma
- first line treatment cell carcinoma